The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Progress for gilteritinib and quizartinib for AML in the first-line setting
The FLT3 inhibitors quizartinib and gilteritinib have made great progress in the relapsed/refractory acute myeloid leukemia (AML) space; however, they may be able to exert more of a benefit in the upfront setting, as discussed here by Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. Dr Levis highlights the progress in the first-line setting for both of these drugs. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
